• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Tipirneni Praveen P.

    8/18/25 5:20:19 PM ET
    $HLXB
    Get the next $HLXB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Tipirneni Praveen P.

    (Last) (First) (Middle)
    BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
    256 EAST GRAND AVENUE, SUITE 104

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/11/2025
    3. Issuer Name and Ticker or Trading Symbol
    BridgeBio Oncology Therapeutics, Inc. [ BBOT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) (1) 12/25/2034 Common Stock 81,069 $5.18 D
    Stock Option (Right to Buy) (2) 04/02/2035 Common Stock 4,855 $7.88 D
    Explanation of Responses:
    1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of November 11, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.
    2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Aaron Chan,Attorney-in-Fact 08/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HLXB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLXB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tipirneni Praveen P.

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/28/25 4:44:27 PM ET
    $HLXB

    SEC Form 4 filed by Director Mccormick Frank

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/28/25 4:43:27 PM ET
    $HLXB

    SEC Form 4 filed by Director Bauer Jake

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    8/28/25 4:41:23 PM ET
    $HLXB

    $HLXB
    SEC Filings

    View All

    SEC Form S-1 filed by Helix Acquisition Corp. II

    S-1 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    8/29/25 4:08:27 PM ET
    $HLXB

    SEC Form EFFECT filed by Helix Acquisition Corp. II

    EFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    8/20/25 12:15:09 AM ET
    $HLXB

    SEC Form SCHEDULE 13G filed by Helix Acquisition Corp. II

    SCHEDULE 13G - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

    8/18/25 5:59:19 PM ET
    $HLXB

    $HLXB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern

    3/5/26 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar

    11/12/25 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

    Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ("PIPE"), led by Cormorant Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the PIPE provides approximately $382 million in gross proceeds Net proceeds will be used to accelerate the development of BBOT's pipeline of clinical-stage RAS-targeted oncology drug candidat

    8/11/25 4:30:00 PM ET
    $HLXB

    $HLXB
    Leadership Updates

    Live Leadership Updates

    View All

    BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar

    11/12/25 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLXB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    11/14/24 1:22:40 PM ET
    $HLXB

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    2/23/24 4:30:20 PM ET
    $HLXB

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

    2/23/24 4:01:43 PM ET
    $HLXB